Structure and trafficking potentials of Botulinum Neurotoxin in drug delivery
by Nagarajan Thirunavukkarasu, Bal Ram Singh
The Botulinum J. (TBJ), Vol. 1, No. 4, 2010

Abstract: Therapeutic options and drug targets for many neurological disorders are very limited. Clinical failure of potentially effective therapeutics, particularly to the CNS, is often not due to lack of potency but rather due to the shortcomings in the drug delivery methods. Clostridial toxins, viz., Tetanus and Botulinum neurotoxins, provide unique opportunities to fulfil some of these unmet requirements in drug delivery. However, clinical application of tetanus-toxin-derived fragments that have been tested in drug delivery, would be potentially limited due to general immunisation. Herein, we describe potential alternative of using non-toxic botulinum neurotoxin serotype A (BoNT/A) derivatives for neuronal drug delivery.

Online publication date: Thu, 17-Mar-2011

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the The Botulinum J. (TBJ):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com